207 related articles for article (PubMed ID: 26073737)
1. Phage Display-Derived Cross-Reactive Neutralizing Antibody against Enterovirus 71 and Coxsackievirus A16.
Zhang X; Sun C; Xiao X; Pang L; Shen S; Zhang J; Cen S; Yang BB; Huang Y; Sheng W; Zeng Y
Jpn J Infect Dis; 2016; 69(1):66-74. PubMed ID: 26073737
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice.
Sun S; Jiang L; Liang Z; Mao Q; Su W; Zhang H; Li X; Jin J; Xu L; Zhao D; Fan P; An D; Yang P; Lu J; Lv X; Sun B; Xu F; Kong W; Jiang C
Hum Vaccin Immunother; 2014; 10(10):2885-95. PubMed ID: 25483672
[TBL] [Abstract][Full Text] [Related]
3. Analysis and solution of false-positives when testing CVA16 sera using an antibody assay against the EV71 virus.
Wang C; You A; Tian X; Zhao M; Chen Y; Lin T; Zheng J; Xiao M; Zhang Y; Kuang L; Zhou Z; Zhu B
Virus Res; 2013 Sep; 176(1-2):33-6. PubMed ID: 23707400
[TBL] [Abstract][Full Text] [Related]
4. Crystal Structures of Yeast-Produced Enterovirus 71 and Enterovirus 71/Coxsackievirus A16 Chimeric Virus-Like Particles Provide the Structural Basis for Novel Vaccine Design against Hand-Foot-and-Mouth Disease.
Lyu K; He YL; Li HY; Chen R
J Virol; 2015 Jun; 89(12):6196-208. PubMed ID: 25833050
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of a Trivalent Hand, Foot, and Mouth Disease Vaccine against Enterovirus 71 and Coxsackieviruses A16 and A6 in Mice.
Caine EA; Fuchs J; Das SC; Partidos CD; Osorio JE
Viruses; 2015 Nov; 7(11):5919-32. PubMed ID: 26593938
[TBL] [Abstract][Full Text] [Related]
6. Structures of Coxsackievirus A16 Capsids with Native Antigenicity: Implications for Particle Expansion, Receptor Binding, and Immunogenicity.
Ren J; Wang X; Zhu L; Hu Z; Gao Q; Yang P; Li X; Wang J; Shen X; Fry EE; Rao Z; Stuart DI
J Virol; 2015 Oct; 89(20):10500-11. PubMed ID: 26269176
[TBL] [Abstract][Full Text] [Related]
7. A novel inactivated enterovirus 71 vaccine can elicit cross-protective immunity against coxsackievirus A16 in mice.
Yang L; Liu Y; Li S; Zhao H; Lin Q; Yu H; Huang X; Zheng Q; Cheng T; Xia N
Vaccine; 2016 Nov; 34(48):5938-5945. PubMed ID: 27771182
[TBL] [Abstract][Full Text] [Related]
8. A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice.
Jiang L; Fan R; Sun S; Fan P; Su W; Zhou Y; Gao F; Xu F; Kong W; Jiang C
Vaccine; 2015 Nov; 33(48):6596-603. PubMed ID: 26529072
[TBL] [Abstract][Full Text] [Related]
9. Hexon-modified recombinant E1-deleted adenoviral vectors as bivalent vaccine carriers for Coxsackievirus A16 and Enterovirus 71.
Zhang C; Yang Y; Chi Y; Yin J; Yan L; Ku Z; Liu Q; Huang Z; Zhou D
Vaccine; 2015 Sep; 33(39):5087-94. PubMed ID: 26296491
[TBL] [Abstract][Full Text] [Related]
10. VP2 dominated CD4+ T cell responses against enterovirus 71 and cross-reactivity against coxsackievirus A16 and polioviruses in a healthy population.
Tan S; Tan X; Sun X; Lu G; Chen CC; Yan J; Liu J; Xu W; Gao GF
J Immunol; 2013 Aug; 191(4):1637-47. PubMed ID: 23863902
[TBL] [Abstract][Full Text] [Related]
11. Dynamic change of mother-source neutralizing antibodies against enterovirus 71 and coxsackievirus A16 in infants.
Mao QY; Liao XY; Yu X; Li N; Zhu FC; Zeng Y; Liang ZL; Li FX; Wang JZ; Lu FM; Zhuang H
Chin Med J (Engl); 2010 Jul; 123(13):1679-84. PubMed ID: 20819628
[TBL] [Abstract][Full Text] [Related]
12. Characterizing Enterovirus 71 and Coxsackievirus A16 virus-like particles production in insect cells.
Somasundaram B; Chang C; Fan YY; Lim PY; Cardosa J; Lua L
Methods; 2016 Feb; 95():38-45. PubMed ID: 26410190
[TBL] [Abstract][Full Text] [Related]
13. The compatibility of inactivated-Enterovirus 71 vaccination with Coxsackievirus A16 and Poliovirus immunizations in humans and animals.
Mao Q; Wang Y; Shao J; Ying Z; Gao F; Yao X; Li C; Ye Q; Xu M; Li R; Zhu F; Liang Z
Hum Vaccin Immunother; 2015; 11(11):2723-33. PubMed ID: 25715318
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity studies of bivalent inactivated virions of EV71/CVA16 formulated with submicron emulsion systems.
Lin CW; Liu CC; Lu TC; Liu SJ; Chow YH; Chong P; Huang MH
Biomed Res Int; 2014; 2014():670506. PubMed ID: 25006583
[TBL] [Abstract][Full Text] [Related]
15. A novel combined vaccine based on monochimeric VLP co-displaying multiple conserved epitopes against enterovirus 71 and varicella-zoster virus.
Wu Y; Zhu R; Xu L; Li Y; Li S; Yu H; Li S; Zhu H; Cheng T; Xia N
Vaccine; 2017 May; 35(20):2728-2735. PubMed ID: 28408118
[TBL] [Abstract][Full Text] [Related]
16. Immunological evaluation and comparison of different EV71 vaccine candidates.
Chou AH; Liu CC; Chang JY; Lien SP; Guo MS; Tasi HP; Hsiao KN; Liu SJ; Sia C; Wu SC; Lee MS; Hsiao CH; Wang JR; Chow YH; Chong P
Clin Dev Immunol; 2012; 2012():831282. PubMed ID: 23008736
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies for diagnosis of enterovirus 71.
Xu L; Huang KJ; Ho TS; Liu CC; Lee YR; Lin CY; Shiuan D; Jiang XH
Monoclon Antib Immunodiagn Immunother; 2013 Dec; 32(6):386-94. PubMed ID: 24328741
[TBL] [Abstract][Full Text] [Related]
18. Cross-reactive neutralizing antibody epitopes against Enterovirus 71 identified by an in silico approach.
Kirk K; Poh CL; Fecondo J; Pourianfar H; Shaw J; Grollo L
Vaccine; 2012 Nov; 30(49):7105-10. PubMed ID: 23022400
[TBL] [Abstract][Full Text] [Related]
19. Seroprevalence of antibodies to enterovirus 71 and coxsackievirus A16 among people of various age groups in a northeast province of Thailand.
Lerdsamran H; Prasertsopon J; Mungaomklang A; Klinmalai C; Noisumdaeng P; Sangsiriwut K; Tassaneetrithep B; Guntapong R; Iamsirithaworn S; Puthavathana P
Virol J; 2018 Oct; 15(1):158. PubMed ID: 30326914
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of human enterovirus 71 and coxsackievirus A16 specific immunoglobulin M antibodies for diagnosis of hand-foot-and-mouth disease.
Yu N; Guo M; He SJ; Pan YX; Chen XX; Ding XX; Hao W; Wang YD; Ge SX; Xia NS; Che XY
Virol J; 2012 Jan; 9():12. PubMed ID: 22234169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
